Horizons Ventures
Horizons Ventures, established in 2002, is a Hong Kong-based venture capital firm specializing in seed, early-stage, and late-stage investments. It focuses on disruptive and technology-driven startups, particularly in the areas of artificial intelligence and machine learning, fintech, healthcare technology, and SaaS. The firm has a track record of successful exits, including notable companies like Skype, Siri, Facebook, Summly, and Waze.
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Ottawa
Spiderwort
Series A in 2022
Spiderwort is an innovative company based in Ottawa, Ontario, founded in 2015, focused on developing biomaterials for regenerative medicine. The company specializes in creating cellulose-based biomaterials that serve as living scaffolds, which can be utilized for various medical applications, including spinal cord injury repair and soft tissue regeneration. Spiderwort's products encompass a range of biological and synthetic polymers available in multiple forms, such as powders, gels, membranes, and pastes. Currently in the pre-clinical stage, their novel biomaterials have shown promising results in terms of biocompatibility and the ability to induce angiogenesis, which is the generation of blood vessels within the scaffold. This approach aims to advance the repair and regeneration of tissues within the human body, providing new solutions for challenging medical conditions.
Spiderwort
Seed Round in 2020
Spiderwort is an innovative company based in Ottawa, Ontario, founded in 2015, focused on developing biomaterials for regenerative medicine. The company specializes in creating cellulose-based biomaterials that serve as living scaffolds, which can be utilized for various medical applications, including spinal cord injury repair and soft tissue regeneration. Spiderwort's products encompass a range of biological and synthetic polymers available in multiple forms, such as powders, gels, membranes, and pastes. Currently in the pre-clinical stage, their novel biomaterials have shown promising results in terms of biocompatibility and the ability to induce angiogenesis, which is the generation of blood vessels within the scaffold. This approach aims to advance the repair and regeneration of tissues within the human body, providing new solutions for challenging medical conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.